Esperion Therapeutics Inc (OQ:ESPR)

Apr 07, 2024 02:45 pm ET
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with O
Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with...
Apr 01, 2024 08:00 am ET
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) recent...
Mar 26, 2024 08:00 am ET
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esperion...
Mar 25, 2024 04:00 pm ET
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual...
Mar 22, 2024 06:26 pm ET
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins. They also include new indications for p
Mar 22, 2024 03:10 pm ET
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive...
Mar 22, 2024 11:04 am ET
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular
Inhibiting Regimen) Outcomes Trial1 – – European Commission Decision On Label Update Authorization Applications Are Expected To Be Made In 1H 2024 – ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe...
Feb 27, 2024 06:00 am ET
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “We have recently made major strides as a company, which we believe position us for sustained...
Feb 16, 2024 04:30 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is...
Feb 13, 2024 08:00 am ET
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss...
Feb 01, 2024 02:00 pm ET
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic...
Jan 23, 2024 04:00 pm ET
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares of its common...
Jan 18, 2024 09:15 pm ET
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per...
Jan 18, 2024 04:00 pm ET
Esperion Announces Proposed Public Offering of Common Stock
Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with this offering, Esperion expects to grant the...
Jan 18, 2024 08:00 am ET
Thinking about buying stock in Phoenix Motor, Mereo BioPharma, Esperion Therapeutics, Adagene, or Advanced Micro Devices?
NEW YORK, Jan. 18, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PEV, MREO, ESPR, ADAG, and AMD.
Jan 09, 2024 08:31 am ET
Thinking about buying stock in Grifols, Esperion Therapeutics, Rithm Capital, Applied Optoelectronics, or Seres Therapeutics?
NEW YORK, Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRFS, ESPR, RITM, AAOI, and MCRB.
Jan 08, 2024 08:31 am ET
Thinking about buying stock in Cyclacel Pharmaceuticals, Broadcom, Qualcomm, Esperion Therapeutics, or Arena Group?
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYCC, AVGO, QCOM, ESPR, and AREN.
Jan 05, 2024 08:31 am ET
Thinking about buying stock in Safe & Green Development, Esperion Therapeutics, Ford Motor, Vertex Pharmaceuticals, or LifeMD?
NEW YORK, Jan. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SGD, ESPR, F, VRTX, and LFMD.
Jan 03, 2024 07:00 am ET
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE), the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their...
Jan 03, 2024 07:00 am ET
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.
Dec 18, 2023 08:00 am ET
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The...
Dec 14, 2023 08:31 am ET
Thinking about buying stock in Processa Pharmaceuticals, Adobe Inc, Progressive Corp, Hanryu Holdings, or Esperion Therapeutics?
NEW YORK, Dec. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCSA, ADBE, PGR, HRYU, and ESPR.
Dec 13, 2023 04:00 pm ET
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to include the treatment of primary hyperlipidemia as a qualifier for...
Nov 13, 2023 10:30 am ET
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in...
Nov 11, 2023 11:00 am ET
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized control trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have...
Nov 09, 2023 04:30 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used...
Nov 07, 2023 06:00 am ET
Esperion Reports Third Quarter 2023 Financial Results
Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2023, and provided a business update. “We continued to deliver on our commitments during the third quarter of 2023, posting strong revenue growth,...
Oct 31, 2023 08:00 am ET
Esperion to Participate in Jefferies London Healthcare Conference
Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 14, 2023 at 3:00 AM ET. The...
Oct 24, 2023 08:00 am ET
Esperion to Report Third Quarter 2023 Financial Results on November 7
Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial...
Sep 26, 2023 09:31 am ET
Thinking about buying stock in Pliant Therapeutics, Esperion Therapeutics, Murphy Canyon Acquisition Corp, Limbach Holdings, or Vaccitech?
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLRX, ESPR, CDT, LMB, and VACC.
Sep 12, 2023 10:15 am ET
American College of Cardiology Program to Increase Cholesterol Screenings
The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without...
Aug 28, 2023 08:00 am ET
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11,...
Aug 26, 2023 11:00 am ET
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC)...
Aug 11, 2023 08:00 am ET
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates on prevention and lipid lowering” at the 2023 ESC Congress taking place August 25-28, 2023, in...
Aug 08, 2023 04:15 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on August 8, 2023, the Company granted five new employees 14,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used...
Aug 01, 2023 06:00 am ET
Esperion Reports Second Quarter 2023 Financial Results
Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2023, and provided a business update. “We posted strong results in the second quarter of 2023, reflecting continued prescription growth and an...
Jul 24, 2023 08:00 am ET
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, will participate in a fireside chat on Monday, August 7, 2023 at 9:00 AM ET. The Esperion management...
Jul 17, 2023 06:00 am ET
Esperion to Report Second Quarter 2023 Financial Results on August 1
Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial...
Jul 07, 2023 08:00 am ET
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Session Type:       Poster Session   Date/Time: July 20, 2023: 2:00 – 8:00...
Jun 28, 2023 08:00 am ET
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) for the Company’s oral non-statin products marketed as NILEMDO and NUSTENDI in Europe. The application asks...
Jun 24, 2023 02:30 pm ET
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >- Esperion (NASDAQ: ESPR) announced the results from the pre-specified, primary prevention CLEAR Outcomes subgroup analysis at the 83rd American Diabetes Association...
Jun 15, 2023 02:30 pm ET
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment with statin therapy per unit decrease in LDL-C, as observed in the CLEAR Outcomes study, at the 2023...
Jun 15, 2023 09:31 am ET
Thinking about trading options or stock in Inpixon, DatChat, Esperion Therapeutics, Verastem, or Vision Marine Technologies?
NEW YORK, June 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INPX, DATS, ESPR, VSTM, and VMAR.
Jun 08, 2023 08:00 am ET
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 2023, in San Diego, CA. Session Type:     Late Breaking Poster...
Jun 05, 2023 08:00 am ET
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at ENDO 2023 taking place June 15-18, 2023, in Chicago, IL. On DemandSession Type:Rapid Fire Presentation #10775  Date/Time:June 15, 2023, 12:30 -1:30 p.m. CT  Abstract...
Jun 01, 2023 08:00 am ET
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
Esperion (NASDAQ: ESPR) today announced that it has submitted Supplemental New Drug Applications (sNDA) to the U.S. Food and Drug Administration (FDA) for the Company’s oral non-statin products NEXLETOL and NEXLIZET. In its sNDAs, Esperion seeks to...
May 25, 2023 04:30 pm ET
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed...
May 24, 2023 08:00 am ET
Esperion to Participate in Jefferies Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th, 2023 at 9:00 AM ET. The Esperion management team...
May 12, 2023 04:30 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used...
May 09, 2023 07:00 am ET
Esperion Reports First Quarter 2023 Financial Results
Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “In the first quarter of 2023, we were proud to report clinically meaningful results from our landmark CLEAR...
May 04, 2023 08:30 am ET
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against DSE in the Southern District of New York. The complaint seeks...
May 01, 2023 08:00 am ET
Esperion to Participate in JMP Securities Life Sciences Conference
Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET. To register for the live...
Apr 27, 2023 08:00 am ET
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America Securities 2023 Health Care Conference on Thursday, May 11th, 2023, at 11:40 AM PDT. To register for...
Apr 25, 2023 08:00 am ET
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Following the release, company management will host a webcast at 8:00 a.m. ET to...
Apr 19, 2023 08:42 am ET
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of Currax’s 72 sales representatives to co-promote NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets....
Apr 03, 2023 08:00 am ET
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET. To register for the...
Mar 22, 2023 04:15 pm ET
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and...
Mar 20, 2023 08:00 am ET
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common...
Mar 08, 2023 08:00 am ET
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
Esperion (NASDAQ: ESPR) today announced publication of updated recommendations from the ILEP which advance bempedoic acid utilization in front of injectable PCSK9 inhibitors. The article, entitled “Bempedoic acid in the management of lipid...
Mar 04, 2023 10:30 am ET
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Preve
Esperion (NASDAQ: ESPR) today announced the full results from the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial, which were presented at the American College of Cardiology’s Annual Scientific...
Feb 24, 2023 01:40 pm ET
Esperion Launches New Scientific Website
With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared towards the scientific and medical communities, delivers information about Esperion’s CLEAR program and the...
Feb 23, 2023 08:00 am ET
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that Sheldon Koenig, president and chief executive officer, will present at Cowen’s 43rd annual Health Care Conference on Wednesday, March 8th, 2023 at 9:10 AM ET. To register for the live webcast, follow...
Feb 22, 2023 08:00 am ET
CLEAR Outcomes Company Update Call: Detailed Results Discussion
Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6th, 2023 where Esperion Chief Medical Officer Dr. JoAnne Foody and CLEAR Outcomes Principal Investigator Dr. Steven Nissen will discuss detailed...
Feb 21, 2023 07:00 am ET
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “I’m proud of the entire organization at Esperion and our ability to deliver on the commitments...
Feb 20, 2023 08:00 am ET
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at the American College of Cardiology’s Annual...
Feb 13, 2023 04:30 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on February 13, 2023, the Compensation Committee of Esperion’s Board of Directors granted six new employees 16,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan....
Feb 07, 2023 08:00 am ET
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial markets on Tuesday, February 21, 2023. Following the release, company management will host a webcast...
Jan 11, 2023 11:00 am ET
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic...
Jan 08, 2023 07:00 pm ET
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2022 financial results and highlighted key upcoming anticipated milestones which represent continued execution of the Company’s transformational plan. “Esperion stands...
Dec 19, 2022 04:15 pm ET
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial, which met its primary endpoint, has been accepted as a late-breaking clinical trial at ACC.23/WCC...
Dec 13, 2022 06:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on December 9, 2022, the Compensation Committee of Esperion’s Board of Directors granted 2 new employees 5,600 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan....
Dec 13, 2022 08:00 am ET
Esperion to Participate in January Investor Meetings
Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January...
Dec 07, 2022 08:05 am ET
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
Esperion (NASDAQ: ESPR) today announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in...
Nov 16, 2022 04:00 pm ET
Esperion Appoints Ben Halladay Chief Financial Officer
Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a...
Nov 09, 2022 08:00 am ET
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
Esperion (NASDAQ: ESPR) will host a virtual R&D Day for the investment community today, Wednesday, November 9 at 10:00 AM Eastern time. The R&D Day presentation will feature discussions led by global scientific leaders Professor Peter Libby, MD,...
Nov 02, 2022 08:00 am ET
Esperion to Participate in Jefferies London Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on Wednesday, November 16th, 2022. Event:Jefferies London Healthcare ConferenceDate:Wednesday, November 16th,...
Nov 01, 2022 07:00 am ET
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “During the third quarter of 2022 our team has remained focused on closing out our unprecedented CLEAR Outcomes...
Oct 27, 2022 08:00 am ET
Esperion Hosting Virtual Research & Development Day
Esperion (NASDAQ: ESPR) today announced that it will host a virtual research and development day, featuring Global Scientific Leaders C. Michael Gibson, MS, MD, from Harvard Medical Research Institutes, and Professor Peter Libby, MD, from Brigham...
Oct 19, 2022 04:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on October 18, 2022, the Compensation Committee of Esperion’s Board of Directors granted 5 new employees 14,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The...
Oct 17, 2022 08:02 am ET
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1st, 2022. Following the release, company management will host a webcast at 8:00 a.m....
Aug 30, 2022 08:00 am ET
Esperion to Participate in Upcoming September Investor Conferences
Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare Conference and also participate in H.C. Wainwright’s Annual Global Investment Conference. Event:Morgan...
Aug 26, 2022 08:16 am ET
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the...
Aug 04, 2022 04:05 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new employees 66,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The...
Aug 02, 2022 07:00 am ET
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “Throughout the second quarter of 2022, we have continued to demonstrate consistent growth and we have made...
Jul 25, 2022 03:00 pm ET
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and breadth of basic,...
Jul 12, 2022 08:00 am ET
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, August 2, 2022. Following the release, company management will host a webcast at 8:00 a.m. ET...
Jun 15, 2022 10:40 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Esperion Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, June 15, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR).
Jun 03, 2022 12:30 pm ET
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Esperion (NASDAQ: ESPR) announced findings from a real-world analysis of more than 400,000 patients at high-risk for atherosclerotic cardiovascular disease (ASCVD). The findings were presented at the National Lipid Association Scientific Sessions...
Jun 02, 2022 08:00 am ET
Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies Global Healthcare Conference on June 8th, 2022. Event:2022 Jefferies Global Healthcare...
Jun 01, 2022 04:00 pm ET
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders. "On behalf...
May 31, 2022 08:00 am ET
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
Esperion (NASDAQ: ESPR) today announced five abstracts have been accepted for presentation at the National Lipid Association Scientific Sessions (NLA 2022 Scientific Sessions) being held in-person in Scottsdale, Arizona. “In the wake of the...
May 17, 2022 08:00 am ET
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24th, 2022. Event:H.C. Wainwright...
May 03, 2022 07:00 am ET
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2022 and provided a business update. "During the first quarter of 2022, our team remained focused on our two primary objectives, delivering on our...
May 02, 2022 08:00 am ET
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology. The paper, “Long-term Safety and Efficacy of...
Apr 29, 2022 05:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on April 28, 2022, the Compensation Committee of Esperion’s Board of Directors granted 14 new employees 48,780 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The...
Apr 29, 2022 10:00 am ET
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10th, 2022. Event:Bank of America Securities...
Apr 28, 2022 04:00 pm ET
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern’s...
Apr 25, 2022 08:00 am ET
Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LD
Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term LDL-cholesterol lowering in patients following a recent acute coronary syndrome (ACS) event. The...
Apr 19, 2022 07:00 am ET
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, May 3, 2022. Following the release, company management will host a webcast and conference call...
Apr 13, 2022 08:00 am ET
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology. The paper, “Efficacy and safety of bempedoic acid in patients...
Apr 03, 2022 12:00 pm ET
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The first analysis titled,...
Mar 29, 2022 08:00 am ET
Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21st Annual Healthcare Conference on Tuesday, April 12, 2022. Event:21st Annual Needham Healthcare...
Mar 10, 2022 08:31 am ET
Thinking about buying stock in Marqeta, Ion Geophysical, Northern Dynasty Minerals, Esperion Therapeutics, or Aemetis?
NEW YORK, March 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, IO, NAK, ESPR, and AMTX.
Feb 24, 2022 08:00 am ET
Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the upcoming Cowen 42nd...
Feb 22, 2022 07:00 am ET
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “In 2021, Esperion strengthened its balance sheet and established a strong and efficient...
Feb 08, 2022 08:00 am ET
Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, February 22, 2022. Following the release, company management will host a...
Jan 28, 2022 05:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on January 27, 2022, the Compensation Committee of Esperion’s Board of Directors granted four new employees (i) non-qualified stock options to purchase an aggregate of 100,450 shares of its common...
Jan 11, 2022 08:00 am ET
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2021 financial results and reiterated full-year 2022 operating expense guidance. “2021 was a transitional year for Esperion, as we ushered in a new leadership team,...
Jan 06, 2022 08:00 am ET
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Time....
Jan 04, 2022 08:00 am ET
Esperion Appoints Benjamin O. Looker as General Counsel
Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as a member of the Esperion executive leadership team effective immediately. In his role, Mr. Looker will...
Dec 07, 2021 04:05 pm ET
Esperion Announces Closing of $225 Million Public Offering
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants to purchase an aggregate of up to...
Dec 03, 2021 09:50 am ET
Thinking about buying stock in DiDi Global, New Oriental Education, Longeveron, Carnival Corp, or Esperion Therapeutics?
NEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, EDU, LGVN, CCL, and ESPR.
Dec 02, 2021 11:40 pm ET
Esperion Announces Pricing of $225 Million Public Offering
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of...
Dec 02, 2021 05:00 pm ET
Esperion Announces Proposed Public Offering
Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase...
Nov 12, 2021 07:00 am ET
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts highlighting NEXLETOL tablets at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. “As one of the few companies solely...
Nov 02, 2021 07:00 am ET
Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2021 and provided a business update. “In the past months, we have made significant strides to align our organization and cost structure with the...
Nov 01, 2021 04:01 pm ET
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. AHA Scientific Sessions 2021 On Demand Session Type:Oral...
Nov 01, 2021 07:00 am ET
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to welcome Seth to...
Oct 27, 2021 04:01 pm ET
Esperion to Participate in Upcoming Virtual Investor Conference
Esperion (NASDAQ: ESPR) today announced that members of Esperion’s management team will participate in the upcoming Credit Suisse 30th Annual Healthcare Conference. Event:   Credit Suisse 30th Annual Healthcare ConferenceDate: Tuesday, November 9,...
Oct 25, 2021 07:00 am ET
ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (the “Holders”) of its 4.00% Convertible Senior Subordinated Notes due 2025 (the "Notes"). Under the terms of the...
Oct 18, 2021 07:00 am ET
ESPERION Announces Plan for Transformative Long-Term Growth
Esperion (NASDAQ: ESPR) today announced its plan to align operational and expense structure to better enable future growth for its two first-in-class oral medicines, NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) and...
Oct 12, 2021 08:00 am ET
Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021. Following the release, company management will host a webcast and conference...
Sep 07, 2021 04:01 pm ET
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm Eastern...
Aug 26, 2021 08:00 am ET
Esperion to Participate in Upcoming Virtual Investor Conference
Esperion (NASDAQ: ESPR) today announced that members of Esperion’s management team will participate in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference. Event:Morgan Stanley 19th Annual Global Healthcare...
Aug 03, 2021 07:00 am ET
ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the second quarter ended June 30, 2021 and provided a business update. “During the second quarter we made significant progress strengthening the...
Jul 27, 2021 08:00 am ET
Esperion to Participate in Upcoming Virtual Investor Conference
Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference. Event:BTIG Virtual Biotechnology ConferenceDate:August 9,...
Jul 13, 2021 08:00 am ET
Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webcast and conference...
Jul 01, 2021 05:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on June 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 31 new employees (i) non-qualified stock options to purchase an aggregate of 88,692 shares of its common stock, all...
Jun 28, 2021 07:59 am ET
ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and Chief...
May 24, 2021 08:00 am ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of June. Event: Jefferies Virtual Healthcare ConferenceDate: June 1, 2021Format: Fireside chat & 1:1...
May 17, 2021 09:01 am ET
ESPERION Appoints Sheldon Koenig as President and CEO
ESPERION (NASDAQ: ESPR), today announced the appointment of Sheldon Koenig as president and chief executive officer and board member, effective immediately. With over 30 years of commercial and operational experience as an accomplished leader in...
May 15, 2021 12:00 pm ET
Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
Patients considered intolerant to statin therapy treated with NEXLETOL predicted to experience a further 6.0% absolute reduction in 10-year cardiovascular event risk compared with placebo (p
May 06, 2021 08:00 am ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May. Event:Bank of America 2021 Healthcare ConferenceDate:May 13, 2021Format:Presentation & 1:1...
May 04, 2021 04:01 pm ET
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. “In the first quarter our team was focused on driving new prescription growth...
Apr 28, 2021 04:05 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on April 23, 2021, the Compensation Committee of Esperion’s Board of Directors granted 21 new employees 50,991 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The...
Apr 27, 2021 08:00 am ET
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
Esperion (NASDAQ: ESPR) today announced the peer reviewed publication of the key design paper outlining the baseline characteristics of the enrolled patient population, rationale and design of the CLEAR Outcomes trial evaluating NEXLETOL®...
Apr 26, 2021 04:07 pm ET
Esperion Secures $50 Million Funding from Oberland Capital
Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling $50...
Apr 26, 2021 04:02 pm ET
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) providing Daiichi Sankyo with exclusive rights to commercialize bempedoic acid and the bempedoic...
Apr 12, 2021 04:01 pm ET
Esperion to Report First Quarter 2021 Financial Results May 4, 2021
Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast and conference call...
Apr 06, 2021 08:00 am ET
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 9:30 a.m....
Mar 17, 2021 04:05 pm ET
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
Esperion (NASDAQ: ESPR) today announced that the results of a Phase 2 study evaluating the combination of NEXLETOL® (bempedoic acid) 180 mg Tablet, ezetimibe 10 mg and atorvastatin 20 mg in patients with hypercholesterolemia were published in...
Feb 23, 2021 04:01 pm ET
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “Even though 2020 was an exceptionally challenging year, we made...
Feb 09, 2021 08:00 am ET
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management will host a...
Feb 01, 2021 08:31 am ET
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, PFE, AZN, VIR, and ESPR.
Jan 29, 2021 05:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 10 new employees (i) non-qualified stock options to purchase an aggregate of 150,000 shares of its common stock,...
Jan 13, 2021 06:26 am ET
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2020 financial results and full-year 2021 operating expense guidance. Concurrently, the Company announced that it has entered into a definitive agreement with Serometrix...
Dec 21, 2020 08:00 am ET
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m. Eastern Time....
Dec 16, 2020 03:00 am ET
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics (NASDAQ: ESPR) announced today Swissmedic approval for NILEMDO®* (bempedoic acid) tablet and NUSTENDI®* (bempedoic acid and ezetimibe) tablet, offering new treatment...
Dec 15, 2020 07:00 am ET
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M. Mayleben, president and chief executive...
Nov 13, 2020 09:14 am ET
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Su
Esperion (NASDAQ: ESPR) today announced results of pooled data from four of the company’s Phase 3 trials were presented at the virtual American Heart Association Scientific Sessions 2020 (AHA 2020). Both analyses demonstrated significant lowering...
Nov 12, 2020 06:17 am ET
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant...
Nov 10, 2020 04:30 pm ET
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the...
Nov 06, 2020 05:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion’s Board of Directors granted 33,663 restricted stock units (RSUs) to 24 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan....
Nov 02, 2020 04:01 pm ET
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
ESPERION (NASDAQ:ESPR) today reported financial results for the third quarter ended September 30, 2020, and provided a business update. “The trajectory of our U.S. launches is encouraging as quarterly script growth increased over 500 percent and...
Oct 27, 2020 08:00 am ET
Esperion to Participate in Three Upcoming Virtual Investor Conferences
Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month of November. Event: Credit Suisse 29th Annual Virtual Healthcare ConferenceDate: November 9,...
Oct 19, 2020 08:00 am ET
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020. Following the release, company management will host a webcast and conference...
Oct 07, 2020 08:00 am ET
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual 88th Annual Congress of the European Atherosclerosis Society (EAS 2020). Both trials demonstrated significant...
Sep 28, 2020 04:06 pm ET
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patient cycle of diet,...
Sep 02, 2020 08:41 am ET
Esperion to Participate in Two Upcoming Virtual Investor Conferences
Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September. Event: Citi 15th Annual Biopharma ConferenceDate: September 9, 2020Format:1:1 Investor...
Aug 26, 2020 09:07 am ET
Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL® (bempedoic acid) tablets as well as long-term safety and efficacy data from the CLEAR Harmony open-label extension study of...
Aug 21, 2020 04:05 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on August 19, 2020, the Compensation Committee of Esperion’s Board of Directors granted 25,566 restricted stock units (RSUs) to 28 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan....
Aug 10, 2020 04:04 pm ET
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
Esperion (NASDAQ:ESPR) today reported financial results for the second quarter ended June 30, 2020, which included the highest quarterly and first half revenue in Company history and other updates, including the establishment of a strong commercial...
Aug 03, 2020 07:26 am ET
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and conference call at 4:30...
Jul 01, 2020 11:12 am ET
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bemp
Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association (JAMA)...
Jun 22, 2020 07:00 am ET
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE).  Earlier this month, Esperion completed the transfer to DSE of Marketing Authorization Approvals (MAA)...
Jun 14, 2020 09:30 am ET
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Session
Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80th Scientific Sessions.  According to the American Diabetes Association (ADA)...
Jun 12, 2020 07:19 am ET
Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including the clinical cost effectiveness and...
Jun 08, 2020 08:00 am ET
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020, at 4:40...
Jun 04, 2020 07:00 am ET
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
Esperion (NASDAQ: ESPR) announced today that NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in U.S. pharmacies.  NEXLIZET...
May 27, 2020 08:00 am ET
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference 2020 on Tuesday, June 2, 2020, at 1:30 p.m....
May 15, 2020 06:00 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902 restricted stock units (RSUs) to 194 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan....
May 07, 2020 08:00 am ET
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at 9:00 a.m. Eastern...
May 06, 2020 04:05 pm ET
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
Esperion (NASDAQ:ESPR) today reported financial results for the first quarter ended March 31, 2020, which included the first-ever product sales revenue for NEXLETOL™ tablets, and provided other company updates. “With two marketing approvals in...
Apr 30, 2020 08:00 am ET
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following the release, company management will host a webcast and conference call at 4:30 p.m....
Apr 20, 2020 07:00 am ET
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
Esperion (NASDAQ: ESPR) today announced that they have entered into a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of NEXLETOL and NEXLIZET tablets in Japan.  Both medicines were recently...
Apr 09, 2020 08:00 am ET
Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020, at 12:50 p.m....
Apr 06, 2020 07:05 am ET
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Esperion (NASDAQ: ESPR) announced today the European Commission approved the NUSTENDI™ (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hypercholesterolemia and dyslipidemia in...
Apr 06, 2020 07:00 am ET
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Esperion (NASDAQ: ESPR) announced today the European Commission approved the NILEMDO™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine. NILEMDO is a first-in-class ATP Citrate Lyase (ACL) inhibitor...
Mar 30, 2020 04:15 pm ET
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
Esperion (NASDAQ: ESPR) announced today that NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. Esperion is committed to respecting the valuable time of...
Mar 28, 2020 09:30 am ET
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scienti
Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69th Scientific Session...
Mar 23, 2020 07:30 am ET
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Ta
Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 69th Scientific...
Mar 18, 2020 07:30 am ET
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan...
Feb 28, 2020 04:15 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,900 shares of its common stock and 59,291 restricted...
Feb 28, 2020 07:00 am ET
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences: Cowen 40th Annual Health Care Conference in Boston Monday, March 2, 2020 11:20 AM EST Barclays Global Healthcare Conference...
Feb 27, 2020 07:00 am ET
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019. “2019 was a precedent setting year for our Lipid Management Team highlighted by the January...
Feb 26, 2020 05:30 pm ET
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved NEXLIZET™  (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C), lowering medicine. NEXLIZET is indicated as...
Feb 21, 2020 04:38 pm ET
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to...
Jan 31, 2020 07:02 am ET
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixe
Esperion (NASDAQ: ESPR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the MAA for the bempedoic acid / ezetimibe fixed dose combination...
Jan 31, 2020 07:01 am ET
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Esperion (NASDAQ: ESPR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the MAA for the bempedoic acid tablet, recommending approval for the...
Jan 07, 2020 07:30 am ET
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2020 at 12:00 p.m. Pacific...
Jan 03, 2020 04:15 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358 restricted stock units (RSUs) to one new colleague under Esperion’s 2017 Inducement Equity Incentive Plan....
Nov 22, 2019 06:30 pm ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705 restricted stock units (RSUs) to fifty-four new colleagues under Esperion’s 2017 Inducement Equity...
Nov 17, 2019 03:05 pm ET
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is being developed as a...
Nov 12, 2019 11:05 am ET
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
Esperion (NASDAQ: ESPR) is pleased to announce that the results from the 779 patient, 52 week, Phase 3, double-blind, randomized placebo-controlled study of bempedoic acid (Study 2, also known as CLEAR Wisdom) were published today in the Journal...
Nov 07, 2019 07:30 am ET
Esperion to Participate in Upcoming Investor Conferences
Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th Annual Healthcare Conference in Phoenix on Tuesday, November 12, 2019 3:50 PM ESTStifel Healthcare...
Nov 06, 2019 07:30 am ET
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. “The Esperion Lipid Management Team continues to lay a strong and durable foundation...
Nov 04, 2019 07:30 am ET
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17, 2019.   Bempedoic...
Oct 29, 2019 07:30 am ET
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic Acid Bempedoic acid is our lead, non-statin, orally available, once-daily,...
Oct 25, 2019 10:00 am ET
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd. The Summit was comprised of a panel of physicians and...
Sep 05, 2019 07:30 am ET
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial. The trial is designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events in patients...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.